All In Biotech

Drug Trial Radar · NCT02736656

Open-label Study to Evaluate Long-term Safety and Efficacy of SPN-812 (Viloxazine Extended-release Capsule)

Open-Label Extension Study to Evaluate the Long Term Safety and Efficacy of SPN-812 for the Treatment of Pediatric Patients With Attention-Deficit/Hyperactivity Disorder (ADHD)

Last checked: Nov 20, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

1,400

Planned (sponsor's estimate)

Start

Feb 2, 2016

Primary completion

Dec 2026

Study completion Dec 2026

Sponsor

Lead sponsor
Supernus Pharmaceuticals, Inc.Industry
Sponsor type
Industry
First posted
Apr 13, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 4 years, up to 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Open label extension, long-term multicenter study of safety and efficacy of SPN-812 in pediatric ADHD patients

Conditions

  • Attention-Deficit/Hyperactivity Disorder

Interventions

  • SPN-812Drug

    Cohort 'A': Children 6-11 yrs of age take 100-400mg SPN-812 once daily by mouth and adolescents 12-17 yrs of age take 100-600mg SPN-812 once daily by mouth. Pediatric subjects in Cohort 'A' are given a choice to extend their participation in the study every 6 months for up to 72 months. Cohort 'B': Pre-school-age children 4-5 yrs of age take 100mg SPN-812 once daily by mouth. Pediatric subjects in Cohort 'B' will be treated with 100 mg SPN-812 (100 mg capsule) for up to 6 months.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of adverse eventsTime frame: up to 72 months

Locations

16 sites in 1 country. Site status is shown where the registry gives one.

  • Woodland International Research Group

    Little Rock, Arkansas

  • Alliance for Wellness dba Alliance for Research

    Long Beach, California

  • MCB Clinical Research Centers, LLC

    Colorado Springs, Colorado

  • Meridien Research at Florida Clinical Research Center

    Bradenton, Florida

  • Sarkis Clinical Trials

    Gainesville, Florida

  • Indago Research & Health Center, Inc.

    Hialeah, Florida

  • Florida Clinical Research Center, LLC.

    Maitland, Florida

  • Florida Clinical Research Center, LLC

    Maitland, Florida

  • IPS Research

    Oklahoma City, Oklahoma

  • Paradigm Research Professionals

    Oklahoma City, Oklahoma

  • Clinical Neuroscience Solutions, Inc.

    Memphis, Tennessee

  • CNS Healthcare

    Memphis, Tennessee

  • Bayou City Research Corporation

    Houston, Texas

  • Road Runner Research

    San Antonio, Texas

  • Ericksen Research & Development

    Clinton, Utah

  • Northwest Clinical Trials

    Bellevue, Washington

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.